Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model

Penza, Velia; Maroun, Justin W.; Nace, Rebecca A.; Schulze, Autumn J; Russell, Stephen J.

doi:10.1016/j.omto.2022.11.006

Molecular Therapy - Oncolytics

2023

DOI: 10.1016/j.omto.2022.11.006

|View full text |Cite

Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model

Velia Penza

Justin W. Maroun

Rebecca A. Nace

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 81 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

Gujar,

Pol,

Kumar

et al. 2024

Nat Protoc

View full text Add to dashboard Cite

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

Gujar,

Pol,

Kumar

et al. 2024

Nat Protoc

View full text Add to dashboard Cite

miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses

Toropko,

Chuvpilo,

Karabelsky

2024

Pharmaceutics

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression by inhibiting the translation of target transcripts. The expression profiles of miRNAs vary in different tissues and change with the development of diseases, including cancer. This feature has begun to be used for the modification of oncolytic viruses (OVs) in order to increase their selectivity and efficacy. OVs represent a relatively new class of anticancer drugs; they are designed to replicate in cancer tumors and destroy them. These can be natural viruses that can replicate within cancer tumor cells, or recombinant viruses created in laboratories. There are some concerns regarding OVs’ toxicity, due to their ability to partially replicate in healthy tissues. In addition, lytic and immunological responses upon OV therapy are not always sufficient, so various OV editing methods are used. This review discusses the latest results of preclinical and clinical studies of OVs, modifications of which are associated with the miRNA-mediated mechanism of gene silencing.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model

Cited by 2 publications

References 81 publications

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses

Contact Info

Product

Resources

About